PatentVest Report Illuminates Patent Strategies Driving the Next Wave of Triple-Agonist Obesity Therapies
Comprehensive analysis of 27 global programs reveals how IP positioning and delivery innovations will shape the post-GLP-1 obesity treatment market
PatentVest’s latest report offers an in-depth examination of the evolving obesity therapeutics landscape, focusing on the competitive patent environment surrounding triple-agonist drugs like Eli Lilly’s retatrutide. The study highlights the strategic importance of intellectual property, receptor-ratio engineering, and…